Subcutaneous formulation of XBiotech's bermekimab successful in mid-stage study

… trial evaluating a subcutaneous formulation of XBiotech's (NASDAQ:XBIT) bermekimab in patients with moderate-to-severe hidradenitis suppurativa …

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *